Cargando…
Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far?
Cancers derive from step by step processes which are differentiated by the progressively accumulated mutations. For some tumors there is a clear progressive advancement from benign lesions to malignancy and for these, preventive screening programs exist. In such cases having those benign lesions are...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309127/ https://www.ncbi.nlm.nih.gov/pubmed/30627525 http://dx.doi.org/10.3389/fonc.2018.00644 |
_version_ | 1783383345217929216 |
---|---|
author | de Melo, Fabiana Henriques Machado Oliveira, Julia Salles Sartorelli, Viviani Olivastro Bressani Montor, Wagner Ricardo |
author_facet | de Melo, Fabiana Henriques Machado Oliveira, Julia Salles Sartorelli, Viviani Olivastro Bressani Montor, Wagner Ricardo |
author_sort | de Melo, Fabiana Henriques Machado |
collection | PubMed |
description | Cancers derive from step by step processes which are differentiated by the progressively accumulated mutations. For some tumors there is a clear progressive advancement from benign lesions to malignancy and for these, preventive screening programs exist. In such cases having those benign lesions are a clear indicator of predisposition while for some other cases, familial patterns of cancer incidence and the identification of mutations are the main indicators of higher risk for having the disease. For patients identified as having predisposition, chemoprevention is a goal and in some cases a possibility. Chemoprevention is the use of any compound, either natural or synthetic that abrogates carcinogenesis or tumor progression, through different mechanisms, some of which have already been described. For example, the classic mechanisms may involve activation of free radical scavenging enzymes, control of chronic inflammation, and downregulation of specific signaling pathways. More recently, epigenetics allowed further understanding of the chemopreventive potential of several agents, such as sulforaphane, green tea derived compounds, resveratrol, isoflavones, and others which we exploit in this review article. Throughout the text we discuss the properties compounds should have in order to be classified as chemopreventive ones and the challenges in translational research in this area, as lots of the success achieved in vitro cannot be translated into the clinical settings, due to several different drawbacks, which include toxicity, cost, dose definition, patient adherence, and regimen of use. |
format | Online Article Text |
id | pubmed-6309127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63091272019-01-09 Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far? de Melo, Fabiana Henriques Machado Oliveira, Julia Salles Sartorelli, Viviani Olivastro Bressani Montor, Wagner Ricardo Front Oncol Oncology Cancers derive from step by step processes which are differentiated by the progressively accumulated mutations. For some tumors there is a clear progressive advancement from benign lesions to malignancy and for these, preventive screening programs exist. In such cases having those benign lesions are a clear indicator of predisposition while for some other cases, familial patterns of cancer incidence and the identification of mutations are the main indicators of higher risk for having the disease. For patients identified as having predisposition, chemoprevention is a goal and in some cases a possibility. Chemoprevention is the use of any compound, either natural or synthetic that abrogates carcinogenesis or tumor progression, through different mechanisms, some of which have already been described. For example, the classic mechanisms may involve activation of free radical scavenging enzymes, control of chronic inflammation, and downregulation of specific signaling pathways. More recently, epigenetics allowed further understanding of the chemopreventive potential of several agents, such as sulforaphane, green tea derived compounds, resveratrol, isoflavones, and others which we exploit in this review article. Throughout the text we discuss the properties compounds should have in order to be classified as chemopreventive ones and the challenges in translational research in this area, as lots of the success achieved in vitro cannot be translated into the clinical settings, due to several different drawbacks, which include toxicity, cost, dose definition, patient adherence, and regimen of use. Frontiers Media S.A. 2018-12-21 /pmc/articles/PMC6309127/ /pubmed/30627525 http://dx.doi.org/10.3389/fonc.2018.00644 Text en Copyright © 2018 Melo, Oliveira, Sartorelli and Montor. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology de Melo, Fabiana Henriques Machado Oliveira, Julia Salles Sartorelli, Viviani Olivastro Bressani Montor, Wagner Ricardo Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far? |
title | Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far? |
title_full | Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far? |
title_fullStr | Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far? |
title_full_unstemmed | Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far? |
title_short | Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far? |
title_sort | cancer chemoprevention: classic and epigenetic mechanisms inhibiting tumorigenesis. what have we learned so far? |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309127/ https://www.ncbi.nlm.nih.gov/pubmed/30627525 http://dx.doi.org/10.3389/fonc.2018.00644 |
work_keys_str_mv | AT demelofabianahenriquesmachado cancerchemopreventionclassicandepigeneticmechanismsinhibitingtumorigenesiswhathavewelearnedsofar AT oliveirajuliasalles cancerchemopreventionclassicandepigeneticmechanismsinhibitingtumorigenesiswhathavewelearnedsofar AT sartorellivivianiolivastrobressani cancerchemopreventionclassicandepigeneticmechanismsinhibitingtumorigenesiswhathavewelearnedsofar AT montorwagnerricardo cancerchemopreventionclassicandepigeneticmechanismsinhibitingtumorigenesiswhathavewelearnedsofar |